Rishi Lulla

3.0k total citations
54 papers, 1.4k citations indexed

About

Rishi Lulla is a scholar working on Genetics, Molecular Biology and Neurology. According to data from OpenAlex, Rishi Lulla has authored 54 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 27 papers in Molecular Biology and 12 papers in Neurology. Recurrent topics in Rishi Lulla's work include Glioma Diagnosis and Treatment (26 papers), Neuroblastoma Research and Treatments (10 papers) and Histone Deacetylase Inhibitors Research (8 papers). Rishi Lulla is often cited by papers focused on Glioma Diagnosis and Treatment (26 papers), Neuroblastoma Research and Treatments (10 papers) and Histone Deacetylase Inhibitors Research (8 papers). Rishi Lulla collaborates with scholars based in United States, Japan and Switzerland. Rishi Lulla's co-authors include Amanda Saratsis, Rintaro Hashizume, Stewart Goldman, C. David James, Craig Horbinski, Ali Shilatifard, Andrea Piunti, Tadanori Tomita, Marcelo B. Soares and Jared M. Bischof and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Rishi Lulla

51 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rishi Lulla United States	17	871	571	415	247	217	54	1.4k
Pankaj Pathak India	22	545 0.6×	584 1.0×	359 0.9×	196 0.8×	106 0.5×	54	1.1k
Andrea Piunti United States	21	1.7k 2.0×	295 0.5×	278 0.7×	112 0.5×	174 0.8×	34	2.0k
Christian J. Davidson United States	9	383 0.4×	422 0.7×	312 0.8×	127 0.5×	227 1.0×	17	930
Benjamin Alderete United States	9	913 1.0×	490 0.9×	250 0.6×	115 0.5×	303 1.4×	17	1.3k
Kui Ming Chan Hong Kong	19	1.1k 1.3×	256 0.4×	311 0.7×	82 0.3×	184 0.8×	36	1.5k
Mamie Yu United States	10	1.3k 1.5×	252 0.4×	1.1k 2.6×	95 0.4×	193 0.9×	12	1.7k
Jana Karásková Canada	17	870 1.0×	248 0.4×	333 0.8×	108 0.4×	379 1.7×	22	1.4k
I‐Mei Siu United States	16	494 0.6×	292 0.5×	190 0.5×	121 0.5×	160 0.7×	22	823
Neelam Shirsat India	22	692 0.8×	233 0.4×	331 0.8×	98 0.4×	193 0.9×	53	1.1k
Gayatry Mohapatra United States	14	743 0.9×	168 0.3×	320 0.8×	486 2.0×	517 2.4×	26	1.4k

Countries citing papers authored by Rishi Lulla

Since Specialization

Citations

This map shows the geographic impact of Rishi Lulla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rishi Lulla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rishi Lulla more than expected).

Fields of papers citing papers by Rishi Lulla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rishi Lulla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rishi Lulla. The network helps show where Rishi Lulla may publish in the future.

Co-authorship network of co-authors of Rishi Lulla

This figure shows the co-authorship network connecting the top 25 collaborators of Rishi Lulla. A scholar is included among the top collaborators of Rishi Lulla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rishi Lulla. Rishi Lulla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Wen-I, Joshua N. Honeyman, Aditi Sharma, et al.. (2023). Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.. PubMed. 13(12). 6241–6255. 4 indexed citations

Zhang, Yiqun, Lanlan Zhou, Rishi Lulla, et al.. (2021). EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia. 23(8). 792–810. 37 indexed citations

Li, Daphne, Erin R. Bonner, Kyle Wierzbicki, et al.. (2021). Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Scientific Reports. 11(1). 5098–5098. 48 indexed citations

Zhou, Lanlan, Wen-I Chang, Yiqun Zhang, et al.. (2021). Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.. PubMed. 11(9). 4607–4623. 12 indexed citations

Kieran, Mark W., Liliana Goumnerova, Peter Manley, et al.. (2019). Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro-Oncology. 21(4). 537–546. 66 indexed citations

Cooney, Tabitha, Arzu Onar‐Thomas, Jie Huang, et al.. (2018). DIPG-22. A PHASE 1 TRIAL OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY DIFFUSE INTRINSIC PONTINE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. Neuro-Oncology. 20(suppl_2). i53–i53. 7 indexed citations

Goldman, Stewart, Eugene Hwang, Jin‐Shei Lai, et al.. (2018). PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. Neuro-Oncology. 20(suppl_6). vi201–vi202. 6 indexed citations

Lulla, Rishi, et al.. (2017). Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib. Pediatric Dermatology. 34(3). 337–341. 9 indexed citations

Lauing, Kristen L., Rishi Lulla, Alicia Lenzen, et al.. (2017). IMMU-35. TARGETING IDO1 IN HUMAN PEDIATRIC BRAIN CANCER. Neuro-Oncology. 19(suppl_6). vi120–vi120. 1 indexed citations

10.

Piunti, Andrea, Rintaro Hashizume, Marc A. Morgan, et al.. (2017). Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nature Medicine. 23(4). 493–500. 275 indexed citations

11.

Shaik, Shavali, Shinji Maegawa, Keri Schadler, et al.. (2017). REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget. 9(4). 5233–5250. 11 indexed citations

12.

Kieran, Mark W., Liliana Goumnerova, Peter Manley, et al.. (2016). EPT-14PHASE I STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY WITH AdV-tk AS ADJUVANT TO SURGERY AND RADIATION THERAPY FOR PEDIATRIC MALIGNANT GLIOMA AND RECURRENT EPENDYMOMA. Neuro-Oncology. 18(suppl 3). iii26.4–iii27. 1 indexed citations

13.

Lulla, Rishi, Stewart Goldman, Tohru Yamada, et al.. (2016). Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology. 18(9). 1319–1325. 117 indexed citations

14.

Ladomersky, Erik, Matthew Genet, Lijie Zhai, et al.. (2016). Improving vaccine efficacy against malignant glioma. OncoImmunology. 5(8). e1196311–e1196311. 16 indexed citations

15.

Gururangan, Sridharan, Oren J. Becher, Sarah Leary, et al.. (2016). EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042). Neuro-Oncology. 18(suppl 3). iii28.1–iii28.

16.

Malchenko, Sergey, Simone Treiger Sredni, Hitoshi Hashimoto, et al.. (2015). A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. PLoS ONE. 10(3). e0121707–e0121707. 6 indexed citations

17.

Goldman, Stewart, Jason Fangusaro, Rishi Lulla, et al.. (2014). PHASE I INDIVIDUAL DOSE TITRATION TRIAL OF THE HUMAN CORTICOTROPIN-RELEASING FACTOR (HCRF), CORTICORELIN ACETATE INJECTION (XERECEPT) IN PEDIATRIC PATIENTS WITH PERITUMORAL EDEMA OF THE BRAIN. Neuro-Oncology. 16(suppl 3). iii23–iii23. 1 indexed citations

18.

Packer, Roger J., Brian R. Rood, David C. Turner, et al.. (2014). Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of Neuro-Oncology. 121(1). 217–224. 20 indexed citations

19.

Costa, Fabrício F., Jared M. Bischof, Elio F. Vanin, et al.. (2011). Identification of MicroRNAs as Potential Prognostic Markers in Ependymoma. PLoS ONE. 6(10). e25114–e25114. 96 indexed citations

20.

Lulla, Rishi, et al.. (2009). Transplacental transfer of postpartum inhibitors to factor VIII. Haemophilia. 16(1). 14–17. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact